| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood cancer journal 11 (8), 138, 2021 | 130 | 2021 |
| Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study M Gavriatopoulou, E Terpos, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Advances 5 (21), 4398-4405, 2021 | 45 | 2021 |
| Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine M Gavriatopoulou, E Terpos, E Kastritis, A Briasoulis, S Gumeni, ... Clinical and Experimental Medicine, 1-5, 2021 | 44 | 2021 |
| Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance E Kastritis, F Theodorakakou, M Roussou, E Psimenou, C Gakiopoulou, ... British Journal of Haematology 193 (1), 113-118, 2021 | 39 | 2021 |
| Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood, The Journal of the American Society of Hematology 139 (9), 1409-1412, 2022 | 35 | 2022 |
| High prevalence of anti-PF4 antibodies following ChAdOx1 nCov-19 (AZD1222) vaccination even in the absence of thrombotic events E Terpos, M Politou, I Ntanasis-Stathopoulos, V Karalis, E Merkouri, ... Vaccines 9 (7), 712, 2021 | 32 | 2021 |
| Robust neutralizing antibody responses 6 months post vaccination with BNT162b2: a prospective study in 308 healthy individuals E Terpos, V Karalis, I Ntanasis-Stathopoulos, M Gavriatopoulou, ... Life 11 (10), 1077, 2021 | 30 | 2021 |
| Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy I Ntanasis-Stathopoulos, V Karalis, M Gavriatopoulou, P Malandrakis, ... Hemasphere 6 (8), e764, 2022 | 26 | 2022 |
| Deep phenotyping reveals distinct immune signatures correlating with prognostication, treatment responses, and MRD status in multiple myeloma K Papadimitriou, N Tsakirakis, P Malandrakis, P Vitsos, A Metousis, ... Cancers 12 (11), 3245, 2020 | 26 | 2020 |
| Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications E Kastritis, M Migkou, D Dalampira, M Gavriatopoulou, D Fotiou, ... American Journal of Hematology 97 (9), 1142-1149, 2022 | 25 | 2022 |
| Whole-genome sequence analysis of an extensively drug-resistant Salmonella enterica serovar Agona isolate from an Australian silver gull (Chroicocephalus novaehollandiae … ML Cummins, M Sanderson-Smith, P Newton, N Carlile, DN Phalen, ... Msphere 5 (6), 10.1128/msphere. 00743-20, 2020 | 25 | 2020 |
| Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome M Gavriatopoulou, I Ntanasis-Stathopoulos, D Fotiou, M Migkou, ... Hemasphere 4 (3), e381, 2020 | 25 | 2020 |
| Comparison of neutralizing antibody responses at 6 months post vaccination with BNT162b2 and AZD1222 E Terpos, V Karalis, I Ntanasis-Stathopoulos, Z Evangelakou, ... Biomedicines 10 (2), 338, 2022 | 22 | 2022 |
| Sustained but declining humoral immunity against SARS-CoV-2 at 9 months postvaccination with BNT162b2: a prospective evaluation in 309 healthy individuals E Terpos, V Karalis, I Ntanasis-Stathopoulos, F Apostolakou, S Gumeni, ... Hemasphere 6 (1), e677, 2022 | 22 | 2022 |
| Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine M Gavriatopoulou, E Terpos, P Malandrakis, I Ntanasis‐Stathopoulos, ... British journal of haematology 196 (2), 356-359, 2022 | 22 | 2022 |
| The role of low dose whole body CT in the detection of progression of patients with smoldering multiple myeloma M Gavriatopoulou, A Βoultadaki, V Koutoulidis, I Ntanasis-Stathopoulos, ... Blood Cancer Journal 10 (9), 93, 2020 | 22 | 2020 |
| Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine … E Terpos, IP Trougakos, V Karalis, I Ntanasis‐Stathopoulos, AD Sklirou, ... American Journal of Hematology 96 (9), E321, 2021 | 18 | 2021 |
| A cancer-related microRNA signature shows biomarker utility in multiple myeloma AM Papanota, P Karousi, CK Kontos, PI Artemaki, CI Liacos, ... International Journal of Molecular Sciences 22 (23), 13144, 2021 | 17 | 2021 |
| XBB. 1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ. 1.1 S Devasundaram, E Terpos, M Rosati, I Ntanasis-Stathopoulos, J Bear, ... American journal of hematology 98 (5), E123, 2023 | 16 | 2023 |
| miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome MA Papadimitriou, AM Papanota, PG Adamopoulos, KM Pilala, CI Liacos, ... British journal of cancer 126 (1), 79-90, 2022 | 16 | 2022 |
